Indication: Multiple Sclerosis (MS)
An Open-Label, Parallel-Group Study To Evaluate Safety, Tolerability, Pharmacokinetics, And Pharmacodynamic Effects Of Ocrelizumab In Children And Adolescents With Relapsing-Remitting Multiple Sclerosis
Sub-indication: Multiple Sclerosis (MS)
Principal Investigator: Michael Sweeney, M.D.Norton Children's Neurology, affiliated with the UofL School of Medicine
Sponsor: F. Hoffmann-LaRoche Ltd.